HIV TAT basic peptide is not a high-affinity ligand for VEGF receptor 2

Area of Science:

• Molecular Biology
• Cell Biology
• Virology

Background:

• The transactivator of transcription (TAT) protein from human immunodeficiency virus is implicated in Kaposi's sarcoma development.
• TAT is known to induce angiogenesis, with a proposed mechanism involving direct activation of VEGF receptor 2 by its basic domain (amino acids 46-64).

Purpose of the Study:

• To investigate the precise interaction sites between the TAT basic domain peptide and VEGF receptor 2.
• To clarify the mechanism by which the TAT peptide contributes to angiogenesis.

Main Methods:

• In vitro binding studies were conducted using recombinant proteins of the extracellular ligand-binding domain of VEGF receptor 2.
• Binding affinity and specificity were assessed between the TAT peptide and different domains of VEGF receptor 2.

Main Results:

• The TAT peptide exhibited low specificity binding to Ig-like domain 3 of VEGF receptor 2.
• In contrast, vascular endothelial growth factor (VEGF) interacts with multiple extracellular domains (1-3) of the receptor.
• These findings indicate that specific, high-affinity interaction with VEGF receptor 2 is not the primary mechanism for TAT-induced angiogenesis.

Conclusions:

• The proposed model of TAT-induced angiogenesis via direct, high-affinity binding to VEGF receptor 2 needs revision.
• TAT likely promotes angiogenesis through multiple cellular interactions, including activation of other cell surface receptors, release of growth factors (VEGF, bFGF), and intracellular signaling pathways.